Business
Press Release Nov 16 2021
Biocon Limited has informed the Exchange regarding a press release dated November 16, 2021, titled "Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE�� (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection".
About this update from Biocon Limited
[{"type":"text","content":" Biocon Limited has informed the Exchange regarding a press release dated November 16, 2021, titled \"Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE�� (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection\". View Attachment","length":443,"tagName":"div"}]